Cyclerion Therapeutics (CYCN) Net Cash Flow (2019 - 2025)

Cyclerion Therapeutics' Net Cash Flow history runs 7 years deep, the most recent figure standing at $1.6 million for Q3 2025.

• In Q3 2025, Net Cash Flow rose 191.03% year-over-year to $1.6 million; the TTM figure through Dec 2025 stood at $1.3 million (up 130.83% YoY), while the FY2024 annual figure was -$4.3 million, up 25.54% from the prior year.
• Net Cash Flow was $1.6 million for Q3 2025 at Cyclerion Therapeutics, up from -$633000.0 in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $25.1 million in Q2 2021 to a low of -$13.0 million in Q1 2021.
• Historically, Net Cash Flow has averaged -$3.1 million across 5 years, with a median of -$1.9 million in 2024.
• Biggest YoY gain for Net Cash Flow was 336.5% in 2021; the steepest drop was 185.52% in 2021.
• A 5-year view of Net Cash Flow shows it stood at -$8.5 million in 2021, then gained by 17.72% to -$7.0 million in 2022, then jumped by 78.08% to -$1.5 million in 2023, then soared by 123.36% to $360000.0 in 2024, then surged by 333.89% to $1.6 million in 2025.
• The last three Net Cash Flow figures came in at $1.6 million (Q3 2025), -$633000.0 (Q2 2025), and $407000.0 (Q1 2025), per Business Quant data.